收藏切换
Efficacy and safety of low-dose venetoclax combined with azacitidine and voriconazole in elderly patients with acute myeloid leukemia
收藏切换
Zhiyuan LI1, Tierong BIAN2, Qian LIU1, Tao MA1, Qulian GUO1, Hongyun XING1, *
World Clinical Drug | 2025, 46(3) : 284 - 290
Less
收藏切换
World Clinical Drug | 2025, 46(3): 284-290
• Article •
Efficacy and safety of low-dose venetoclax combined with azacitidine and voriconazole in elderly patients with acute myeloid leukemia
Full
Zhiyuan LI1, Tierong BIAN2, Qian LIU1, Tao MA1, Qulian GUO1, Hongyun XING1, *
Affiliations
  • 1.Department of Hematology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
  • 2.Medical Molecular Laboratory Center , the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
Published: 2025-03-10 doi: 10.13683/j.wph.2025.03.013
Outline
收藏切换
Objective

To analyze the efficacy of low-dose venetoclax combined with azacitidine and voriconazole in elderly patients with acute myeloid leukemia(AML).

Methods

Clinical data of elderly AML patients hospitalized in the affiliated hospital of southwest medical university from June 2021 to June 2023 were collected. All patients completed 4 cycles of venetoclax combined with azacitidine. The efficacy and safety of different treatment schemes were compared.

Results

A total of 45 patients were enrolled, of which 12 patients were treated with standard dose of venetoclax+azacitidine, and 33 patients were treated with low-dose venetoclax+azacitidine+voriconazole. In the low-dose group, 24 patients(72.7%) were evaluated as complete remission(CR) or CR with incomplete count recovery(CRi) after treatment. A total of 19 patients(57.6%) achieved negative response on minimal residual lesion(MRD). In the standard-dose group, 10 patients(83.3%) were assessed for CRi and 3 patients(25.0%) achieved MRD-negative response. In addition, patients with SRSF2, BCOR, NPM1, or IDH1/2 gene mutations were observed to be more sensitive to treatment. The incidence of granulocytopenia, thrombocytopenia, elevated transaminase, electrolyte disturbance, anemia, hypoproteinemia and infection in low dose group was higher than that in standard dose group. Both the mean and median overall survival(OS)in the standard-dose group were significantly longer than those in the low-dose group.

Conclusion

In the treatment of elderly AML with low-dose venetoclax+azacitidine regimen, combined with voriconazole for antifungal therapy can increase the effective plasma concentration of venetoclax without increasing the CR/CRi rate. However, compared with the standard dose regimen, but treatment-related adverse events increased and OS was shortened.

venetoclax  /  acute myeloid leukemia  /  azacytidine  /  voriconazole
李志远, 卞铁荣, 刘倩, 马涛, 郭渠莲, 邢宏运. 伏立康唑联合低剂量维奈克拉及阿扎胞苷治疗老年急性髓系白血病疗效及安全性. 世界临床药物, 2025 , 46 (3) : 284 -290 . DOI: 10.13683/j.wph.2025.03.013
Zhiyuan LI, Tierong BIAN, Qian LIU, Tao MA, Qulian GUO, Hongyun XING. Efficacy and safety of low-dose venetoclax combined with azacitidine and voriconazole in elderly patients with acute myeloid leukemia[J]. World Clinical Drug, 2025 , 46 (3) : 284 -290 . DOI: 10.13683/j.wph.2025.03.013
Year 2025 volume 46 Issue 3
47
10
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2025.03.013
  • Receive Date:2024-06-22
  • Online Date:2026-11-10
  • Published:2025-03-10
Article Data
Affiliations
History
  • Received:2024-06-22
  • Revised:2024-11-12
Funding
Affiliations
    1.Department of Hematology, the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
    2.Medical Molecular Laboratory Center , the Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.03.013
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT